News Daily News Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES Michael O'Riordan August 26, 2019
News Conference News EAS 2019 Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role Michael O'Riordan June 07, 2019
News Conference News SCAI 2019 LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER Yael L. Maxwell June 03, 2019
News Conference News EAS 2019 CHD Mortality Significantly Elevated in Patients With Severe FH Michael O'Riordan May 29, 2019